Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$241.55+1.18 (+0.49%)
Close on Nov 13, 2026Market cap $15.68BP/E 78.7Yield –
Jazz Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Jazz Pharmaceuticals's cash was $2.86B at Sep 30, 2026. For fiscal 2025 it was $2.44B, up 1.2% from the year before. Over ten years it grew 9.5% a year on average. The highest annual figure on record is $2.44B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.44B | +1.2% |
| FY2024 | Dec 31, 2024 | $2.41B | +60.2% |
| FY2023 | Dec 31, 2023 | $1.51B | +70.9% |
| FY2022 | Dec 31, 2022 | $881.48M | +49.0% |
| FY2021 | Dec 31, 2021 | $591.45M | -44.1% |
| FY2020 | Dec 31, 2020 | $1.06B | +66.0% |
| FY2019 | Dec 31, 2019 | $637.34M | +105.8% |
| FY2018 | Dec 31, 2018 | $309.62M | -19.8% |
| FY2017 | Dec 31, 2017 | $386.04M | +5.5% |
| FY2016 | Dec 31, 2016 | $365.96M | -63.0% |
| FY2015 | Dec 31, 2015 | $988.79M | +44.6% |
| FY2014 | Dec 31, 2014 | $684.04M | +7.5% |
| FY2013 | Dec 31, 2013 | $636.50M | +64.4% |
| FY2012 | Dec 31, 2012 | $387.20M | +145.2% |
| FY2011 | Dec 31, 2011 | $157.90M | +249.4% |
| FY2010 | Dec 31, 2010 | $45.19M | +189.8% |
| FY2009 | Dec 31, 2009 | $15.60M | -37.4% |
| FY2008 | Dec 31, 2008 | $24.90M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.86B | +115.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.20B | +84.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.87B | +54.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.44B | +1.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.33B | -40.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.19B | -12.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.86B | +29.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.41B | +60.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.22B | +66.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.36B | +5.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.44B | +23.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.51B | +70.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.34B | +59.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.28B | +80.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.17B | +137.9% |
| Q4 FY2022 | Dec 31, 2022 | $881.48M | +49.0% |
| Q3 FY2022 | Sep 30, 2022 | $839.36M | +24.9% |
| Q2 FY2022 | Jun 30, 2022 | $711.27M | -20.2% |
| Q1 FY2022 | Mar 31, 2022 | $490.84M | -76.6% |
| Q4 FY2021 | Dec 31, 2021 | $591.45M | -44.1% |
| Q3 FY2021 | Sep 30, 2021 | $671.78M | -9.5% |
| Q2 FY2021 | Jun 30, 2021 | $891.40M | +13.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.10B | +199.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.06B | +66.0% |
| Q3 FY2020 | Sep 30, 2020 | $741.94M | -6.7% |
| Q2 FY2020 | Jun 30, 2020 | $786.08M | +23.3% |
| Q1 FY2020 | Mar 31, 2020 | $701.60M | +28.2% |
| Q4 FY2019 | Dec 31, 2019 | $637.34M | +105.8% |
| Q3 FY2019 | Sep 30, 2019 | $795.18M | +59.3% |
| Q2 FY2019 | Jun 30, 2019 | $637.74M | +31.5% |
| Q1 FY2019 | Mar 31, 2019 | $547.47M | +20.8% |
| Q4 FY2018 | Dec 31, 2018 | $309.62M | -19.8% |
| Q3 FY2018 | Sep 30, 2018 | $499.02M | +97.5% |
| Q2 FY2018 | Jun 30, 2018 | $485.08M | +102.8% |
| Q1 FY2018 | Mar 31, 2018 | $453.17M | +30.6% |
| Q4 FY2017 | Dec 31, 2017 | $386.04M | +5.5% |
| Q3 FY2017 | Sep 30, 2017 | $252.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $239.21M | – |
| Q1 FY2017 | Mar 31, 2017 | $347.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $365.96M | – |
See a number that looks wrong?